Anthony S. Marucci - 15 Aug 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
PRESIDENT & CEO, Director
Signature
/s/ Samuel B. Martin, attorney-in-fact for Anthony S. Marucci
Issuer symbol
CLDX
Transactions as of
15 Aug 2022
Net transactions value
-$3,905,330
Form type
4
Filing time
17 Aug 2022, 16:06:50 UTC
Previous filing
17 Jun 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $208,500 +75,000 +271% $2.78* 102,692 15 Aug 2022 Direct F1
transaction CLDX Common Stock Options Exercise $405,742 +45,000 +44% $9.02 147,692 15 Aug 2022 Direct F2
transaction CLDX Common Stock Sale $4,519,572 -120,000 -81% $37.66 27,692 15 Aug 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -75,000 -75% $0.000000 25,000 15 Aug 2022 Common Stock 75,000 $2.78 Direct F4
transaction CLDX Incentive Stock Option Options Exercise $0 -45,000 -63% $0.000000 26,665 15 Aug 2022 Common Stock 45,000 $9.02 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F2 This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5 As of June 13, 2022, the option is fully vested.